Abbott quarterly sales miss estimates on lower COVID-19 test volumes

imageStock Markets7 minutes ago (Apr 20, 2021 08:55AM ET)

(C) Reuters. FILE PHOTO: Boxes of Abbott’s heart stents are pictured inside a store at a hospital in New Delhi

(Reuters) -Abbott Laboratories fell short of first-quarter revenue estimates on Tuesday, suggesting that the medical device maker may be facing slowing sales of its COVID-19 test kits as vaccinations gain steam.

In the quarter, COVID-19 test kits generated sales of $2.2 billion and accounted for more than half of the diagnostic unit’s revenue. But that compared with $2.4 billion in the prior quarter.

Abbott’s shares fell 3% to $120.67 in trading before the bell.

Rival Quest Diagnostics (NYSE:DGX), which is set to report its quarterly results on April 22, said in February that it was expecting demand for its COVID-19 tests to shrink in the year as vaccination efforts ramp up.

Abbott, Quest and Becton Dickinson (NYSE:BDX) and Co benefited from heightened COVID-19 testing during the early phase of the crisis, a revenue stream that helped blunt the blow from lower demand for medical devices.

Net sales at Abbott increased to $10.5 billion, but fell short of estimates of $10.7 billion, according to IBES data from Refinitiv.

The company reiterated its 2021 adjusted diluted earnings per share outlook of at least $5.00.

Excluding items, the company earned $1.32 per share, above the average analyst estimate of $1.27.

Abbott quarterly sales miss estimates on lower COVID-19 test volumes

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.